Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
Uplizna also hit the target on a number of secondary measures, including: annualised flare rate; flare-free, treatment-free ...
The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
Uplizna is currently approved in the U.S., Europe and Canada, among others, for a rare, severe, neuroinflammatory disease ...
Amgen Inc (NASDAQ:AMGN) announced topline results from its Phase 3 trial evaluating the efficacy and safety of Uplizna ...
Amgen has made waves in the biosimilar field in recent years with its U.S.-first Humira biosim launch last year and its ...
Amgen latest news, photos, videos, breaking news, special reports, blogs, and updates from Business Insider India ...
COVID-19 Vaccines: "We wanted to make sure that we gave people the option to potentially make a choice of a KP2 vaccine. We ...
The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi ...
The world's first human trial of a drug designed to regenerate real teeth is set to commence in jus… ...
FDA staff also said vaccine makers developing the new booster shots may need to consider targeting one of the JN.1 ...
The US Food and Drug Administration approved Cambridge, Massachusetts-based Moderna’s vaccine for a respiratory virus which ...